Could a new oral ketamine capsule ease bipolar depression when other treatments fail?
NCT ID NCT07644767
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral ketamine capsule (KET-AD) designed to be abuse-deterrent in adults with treatment-resistant bipolar depression. About 160 participants will receive either KET-AD or a placebo, taken three times a week for up to 7 weeks, alongside their usual treatment. The goal is to see if it safely improves depressive symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KET-AD (oral ketamine capsule)
- What this could lead to
- If successful, this could offer a new, abuse-deterrent oral option for people with bipolar depression who haven't responded to standard treatments.
- What could go wrong
- This is an early phase 2 trial with a small sample size, so results may not confirm effectiveness. Ketamine can cause side effects like dissociation or nausea, and the abuse-deterrent design is still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-RESISTANT BIPOLAR DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.